Bernd Jilma

ORCID: 0000-0001-5652-7977 · 2 papers in corpus

article 2014

A first-in-human study of PDC31 (prostaglandin F2 receptor inhibitor) in primary dysmenorrhea

·doi:10.1093/humrep/deu205

STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…

article 1997

Menstrual cycle-associated changes in blood levels of interleukin-6, α1 acid glycoprotein, and C-reactive protein

·doi:10.1016/s0022-2143(97)90060-3

Based on previous studies we hypothesized that interleukin-6 (IL-6) plasma levels would increase during the menstrual cycle, in analogy to the increase in IL-1 levels seen during the luteal phase. Thus we have investigated menstrual cycle-a…